Galcanezumab effect on "whole pain burden" and multidimensional outcomes in migraine patients with previous unsuccessful treatments: a real-world experience.

J Headache Pain · 2022 · PMC9195341 · PMID 35698070

Europe PMC DOI

hedged sentence

0.0100

closest p · 0.2× alpha

0.0100

boldest claim

The sentences

did not reach statistical significancep = 0.01actually significant

Cutaneous allodynia symptoms experienced during the attacks (assessed by ASC-12) improved after the third and sixth administration but did not reach statistical significance after correction for multiple comparison ( p = 0.01).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.